Psoriasis News and Research

Latest Psoriasis News and Research

Magnesium essential for absorption and metabolism of vitamin D and calcium

Magnesium deficiency is an important factor in the results obtained from vitamin D. According to Dr. Carolyn Dean, MD, ND, magnesium expert and Medical Director of the nonprofit Nutritional Magnesium Association, the effectiveness and benefits of vitamin D are greatly undermined in the absence of adequate levels of magnesium in the body.

15 Jun 2011

Leukothera effectively treats psoriasis in humanized mouse xenograft transplantation model

Psoriasis is a persistent, long-lasting chronic skin disease affecting 2-3 percent of the world's population or more than 125 million individuals. For some, it is just a nuisance. For others, it is disabling.

15 Jun 2011

Humira defect lawyers file suit against Abbott Laboratories in federal court

Humira defect lawyers filed a lawsuit against Abbott Laboratories in federal court today claiming Abbott's blockbuster drug, Humira, caused a fungal infection resulting in the near-death of a Tennessee man.

14 Jun 2011

NYU Langone webinar discusses advances in the treatment of RA

Steven Abramson, MD, professor of medicine and director of the rheumatology division at NYU Langone Medical Center, hosted a webinar with colleagues from the medical center for rheumatoid arthritis community bloggers - bringing together, bench, bedside and the blogosphere to discuss advances in the investigation, care, and treatment of RA.

13 Jun 2011

OzHealth Pharma, Moberg Derma partner to distribute Emtrix in Australia and New Zealand

Moberg Derma AB has entered into a distribution agreement with OzHealth Pharma for Emtrix - for discolored and damaged nails caused by nail fungus or nail psoriasis.

8 Jun 2011

Topline results from 4SC vidofludimus Phase IIb trial against rheumatoid arthritis

4SC AG, a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced topline results from its randomised, double-blind, placebo-controlled Phase IIb clinical trial COMPONENT in RA.

8 Jun 2011

Bristol-Myers Squibb's second YERVOY Phase 3 trial on metastatic melanoma meets primary endpoint

Bristol-Myers Squibb Company today announced results from a second Phase 3 randomized, double blind study demonstrating that YERVOY (ipilimumab) prolonged the lives of patients with metastatic melanoma.

6 Jun 2011

Roche, Bristol-Myers Squibb to evaluate YERVOY and vemurafenib treatment for metastatic melanoma

Bristol-Myers Squibb Company announced today it has entered in to a clinical collaboration agreement with Roche to evaluate the utility of Bristol-Myers Squibb's CTLA-4 inhibitor, YERVOY (ipilimumab), in combination with Roche's investigational oral BRAF inhibitor, vemurafenib, in treating patients with a specific type of metastatic melanoma.

4 Jun 2011

Leukemia, psoriasis drugs may treat vascular diseases

A drug that has been on the market for decades to treat leukemia and skin disorders such as acne and psoriasis may be a possible therapy for vascular diseases, including atherosclerosis and hypertension, which can lead to heart attack or stroke.

27 May 2011

4SC to present pre-clinical data on vidofludimus in systemic lupus erythematosus at EULAR 2011

4SC AG, a discovery and development company of targeted small molecule drugs for autoimmune and cancer diseases, will present pre-clinical data on vidofludimus - its lead small-molecule drug candidate against autoimmune diseases - in systemic lupus erythematosus at EULAR 2011, Europe's largest scientific conference on rheumatic diseases, in London, UK, from May 25-28, 2011.

27 May 2011

New findings from STELARA psoriasis clinical trial to be presented at 22nd World Congress of Dermatology

New findings to be presented from pooled analyses of the STELARA psoriasis clinical development program showed that the safety profile of STELARA and rates of adverse events remained consistent and stable over time in adults with moderate to severe plaque psoriasis receiving up to four years of treatment.

25 May 2011

Patient accrual complete in Provectus PH-10 Phase 2C clinical trial for treatment of psoriasis

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has completed patient accrual in its Phase 2C clinical trial of PH-10 for the treatment of psoriasis. PH-10, an aqueous hydrogel formulation of Rose Bengal disodium for topical administration to the skin, is being studied for the treatment of cutaneous skin disorders, specifically psoriasis and atopic dermatitis.

24 May 2011

Scientific evidence supports benefits of sunscreen usage to prevent skin cancer

The American Academy of Dermatology today reiterated the safety and effectiveness of sunscreens to protect against the damaging effects from exposure to ultraviolet (UV) radiation. As one component of a daily sun-protection strategy, sunscreen is an important tool in the fight against skin cancer, including melanoma, the deadliest form of skin cancer.

24 May 2011

VBL to present updated VB-111 Phase 1 trial results in advanced metastatic cancer at ASCO 2011

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced that it will present updated results for a Phase 1 study of VB-111 in patients with advanced metastatic cancer at the upcoming Annual Meeting of the American Society of Clinical Oncology, taking place June 3-7, 2011, at McCormick Place in Chicago.

24 May 2011

VBL to present positive VB-111 preclinical data in metastatic lung cancer at 14th ASGCT

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced that it will present preclinical data demonstrating VB-111's potential synergy and additive therapeutic effect when administered in combination with the conventional chemotherapy cancer treatments.

20 May 2011

XTRAC Excimer Laser treatment offers new hope for patients with psoriasis

With XTRAC® Excimer Laser treatments, psoriasis patients can say goodbye to the red, dry patches of scaly, thickened skin they have been covering up all winter. Developed by PhotoMedex, Inc., an innovator of medical devices, the XTRAC laser offers new hope to the 7.5 million Americans suffering from this embarrassing and socially isolating disease.

19 May 2011

Study suggests link between obesity, psoriasis and heart disease risk in children

Children who are overweight or obese have a significantly higher prevalence of psoriasis, and teens with psoriasis, regardless of their body weight, have higher cholesterol levels, according to a Kaiser Permanente study published online in the Journal of Pediatrics.

19 May 2011

Anacor Pharmaceuticals initiates AN2728, AN2898 Phase 2 trial in mild-to-moderate atopic dermatitis

Anacor Pharmaceuticals announced today that the first patient has been dosed in a Phase 2 trial of AN2728 and AN2898 to determine safety, tolerability and efficacy of the two compounds for the topical treatment of mild-to-moderate atopic dermatitis.

18 May 2011

Synexus completes CT327 phase II psoriasis trial for Creabilis

Synexus has completed a phase II study for the European biotech, Creabilis, recruiting 26 patients in the UK to the psoriasis trial of its CT327 lead product in just 2 weeks, as part of an international proof-of-concept study. The company delivered the targeted number of patients well within the agreed timelines and budget.

From AES - Accelerated Enrollment Solutions 16 May 2011

New Crohn’s disease therapy on its way

In a new study on a drug called Stelara (ustekinumab) it was seen that 40% patients with moderate to severe Crohn's disease responded. Stelara, which is already approved to treat psoriasis, is a human interleukin (IL)-12 and IL-23 antagonist marketed by Centocor Ortho Biotech Inc. The study findings were presented at Digestive Disease Week 2011.

11 May 2011

Psoriasis News and Research

Latest Psoriasis News and Research

Magnesium essential for absorption and metabolism of vitamin D and calcium

Leukothera effectively treats psoriasis in humanized mouse xenograft transplantation model

Humira defect lawyers file suit against Abbott Laboratories in federal court

NYU Langone webinar discusses advances in the treatment of RA

OzHealth Pharma, Moberg Derma partner to distribute Emtrix in Australia and New Zealand

Topline results from 4SC vidofludimus Phase IIb trial against rheumatoid arthritis

Bristol-Myers Squibb's second YERVOY Phase 3 trial on metastatic melanoma meets primary endpoint

Roche, Bristol-Myers Squibb to evaluate YERVOY and vemurafenib treatment for metastatic melanoma

Leukemia, psoriasis drugs may treat vascular diseases

4SC to present pre-clinical data on vidofludimus in systemic lupus erythematosus at EULAR 2011

New findings from STELARA psoriasis clinical trial to be presented at 22nd World Congress of Dermatology

Patient accrual complete in Provectus PH-10 Phase 2C clinical trial for treatment of psoriasis

Scientific evidence supports benefits of sunscreen usage to prevent skin cancer

VBL to present updated VB-111 Phase 1 trial results in advanced metastatic cancer at ASCO 2011

VBL to present positive VB-111 preclinical data in metastatic lung cancer at 14th ASGCT

XTRAC Excimer Laser treatment offers new hope for patients with psoriasis

Study suggests link between obesity, psoriasis and heart disease risk in children

Anacor Pharmaceuticals initiates AN2728, AN2898 Phase 2 trial in mild-to-moderate atopic dermatitis

Synexus completes CT327 phase II psoriasis trial for Creabilis

New Crohn’s disease therapy on its way

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Psoriasis News and Research

Latest Psoriasis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in